» Articles » PMID: 3028550

The Effects of N-(cyclopropylmethyl)-19-isopentylnororvinol (M320), a Potent Agonist at Kappa- and Mu-opiate Receptors, on Urine Excretion of Rats

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1986 Dec 1
PMID 3028550
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of N-(cyclopropylmethyl)-19-isopentylnororvinol hydrochloride (M320) on urine excretion by rats were investigated. Further studies, using rabbit isolated vas deferens, investigated its interactions with kappa-opiate receptors. The output of urine for a 2 h period after M320, administered subcutaneously to normally hydrated Long Evans rats, showed a bell-shaped dose-response relationship, the maximum effect occurring after 10 micrograms kg-1. Urinary retention contributed to but did not fully account for the weaker diuresis after high doses. Attenuation of the ascending portion of the dose-response curve to M320 occurred after 1 and 10 mg kg-1 but not 0.1 mg kg-1 of naltrexone intraperitoneally. M320 in low doses (3-10 micrograms kg-1) caused a small but significant increase in sodium excretion. M320 (30 micrograms kg-1) reduced both sodium and potassium excretion. M320 (10 micrograms kg-1 s.c.) did not increase the volume of urine voided in 2 h by Brattleboro rats showing diabetes insipidus, even when urine excretion was reduced to normal by 1 week of vasopressin replacement. The volume of urine voided in 4 h by Brattleboro rats was progressively reduced to zero by M320 (10-100 micrograms kg-1 s.c.). Urinary retention contributed to but did not account for this reduction. Plasma levels of immunoreactive arginine vasopressin (ir-AVP) were reduced in both normal and dehydrated Long Evans rats after doses greater than 1 microgram kg-1 M320 s.c. In vitro, M320 caused persistent inhibition of twitches of the electrically stimulated rabbit vas deferens (IC50 1.7 nM). 8 These data suggest that M320 has potent opioid agonist activity at K-receptors and at higher concentrations stimulates mu- receptors. In the rat, its activity on K-receptors is associated with diuresis and suppression of plasma vasopressin levels. The antidiuresis seen after high doses may be due to its activity on mu-receptors, possibly at a central site.

Citing Articles

Chronic recurrent dehydration associated with periodic water intake exacerbates hypertension and promotes renal damage in male spontaneously hypertensive rats.

Hilliard L, Mirabito Colafella K, Bulmer L, Puelles V, Singh R, Ow C Sci Rep. 2016; 6:33855.

PMID: 27653548 PMC: 5032121. DOI: 10.1038/srep33855.


Actions of tramadol on micturition in awake, freely moving rats.

Pandita R, Pehrson R, Christoph T, Friderichs E, Andersson K Br J Pharmacol. 2003; 139(4):741-8.

PMID: 12812997 PMC: 1573893. DOI: 10.1038/sj.bjp.0705297.


Studies of the effects of subacute treatment with N-(cyclopropylmethyl)-19-isopentylnororvinol (M320) on timing of parturition in the rat.

Evans R, Rice G, Olley J Br J Pharmacol. 1988; 95(3):777-82.

PMID: 3207993 PMC: 1854236. DOI: 10.1111/j.1476-5381.1988.tb11704.x.

References
1.
Boura A, FITZGERALD A . The pharmacology of N-(cyclopropylmethyl)-19-isopentylnororvinol hydrochloride. A potent and long lasting central depressant. Br J Pharmacol Chemother. 1966; 26(2):307-21. PMC: 1510649. DOI: 10.1111/j.1476-5381.1966.tb01910.x. View

2.
Leander J . Further study of kappa opioids on increased urination. J Pharmacol Exp Ther. 1983; 227(1):35-41. View

3.
Huidobro F . Antidiuretic effect of morphine and vasopressin in morphine tolerant and non-tolerant rats, differential effects on urine composition. Eur J Pharmacol. 1979; 59(1-2):55-64. DOI: 10.1016/0014-2999(79)90024-4. View

4.
Romer D, Buscher H, Hill R, Maurer R, Petcher T, Welle H . Bremazocine: a potent, long-acting opiate kappa-agonist. Life Sci. 1980; 27(11):971-8. DOI: 10.1016/0024-3205(80)90107-1. View

5.
Huidobro-Toro J . Antidiuretic effect of beta-endorphin and morphine in Brattleboro rats: development of tolerance and physical dependence after chronic morphine treatment. Br J Pharmacol. 1980; 71(1):51-6. PMC: 2044393. DOI: 10.1111/j.1476-5381.1980.tb10908.x. View